{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:12:06Z","timestamp":1773299526330,"version":"3.50.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.cld.2008.02.008","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T10:00:23Z","timestamp":1210327223000},"page":"425-443","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents"],"prefix":"10.1016","volume":"12","author":[{"given":"Marina G.","family":"Silveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9377","key":"10.1016\/j.cld.2008.02.008_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","article-title":"Primary biliary cirrhosis","volume":"362","author":"Talwalkar","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.mcg.0000225653.07932.8f","article-title":"Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy","volume":"41","author":"Lazaridis","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4065\/73.2.179","article-title":"Ludwig Symposium on biliary disorders\u2014part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"73","author":"Scheuer","year":"1998","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.cld.2008.02.008_bib5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","article-title":"Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients","volume":"78","author":"Christensen","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/j.cld.2008.02.008_bib9","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJM198906293202602","article-title":"Efficiency of liver transplantation in patients with primary biliary cirrhosis","volume":"320","author":"Markus","year":"1989","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cld.2008.02.008_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMct074694","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis","volume":"357","author":"Lindor","year":"2007","journal-title":"N Engl J\u00a0Med"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib11","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1053\/gast.1996.v110.pm8613058","article-title":"Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis","volume":"110","author":"Lindor","year":"1996","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.cld.2008.02.008_bib16","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/he.2000.5984","article-title":"Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines","volume":"31","author":"Heathcote","year":"2000","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.cld.2008.02.008_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF01308413","article-title":"Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study","volume":"30","author":"Leuschner","year":"1985","journal-title":"Dig Dis Sci"},{"issue":"8537","key":"10.1016\/j.cld.2008.02.008_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2008.02.008_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/BF01391378","article-title":"Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II","volume":"27","author":"Bachrach","year":"1982","journal-title":"Dig Dis Sci"},{"issue":"12 Suppl","key":"10.1016\/j.cld.2008.02.008_bib23","doi-asserted-by":"crossref","first-page":"59S","DOI":"10.1007\/BF01536665","article-title":"Effect of different doses of ursodeoxycholic acid in chronic liver disease","volume":"34","author":"Podda","year":"1989","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0168-8278(96)80293-5","article-title":"Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response","volume":"25","author":"van de Meeberg","year":"1996","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol"},{"issue":"22","key":"10.1016\/j.cld.2008.02.008_bib27","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib29","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2008.02.008_bib30","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1111\/j.1572-0241.2002.06043.x","article-title":"Results of long-term ursodiol treatment for patients with primary biliary cirrhosis","volume":"97","author":"Jorgensen","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1572-0241.1998.00287.x","article-title":"Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy","volume":"93","author":"Zukowski","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib34","first-page":"389","article-title":"Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?","volume":"21","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"issue":"265","key":"10.1016\/j.cld.2008.02.008_bib35","first-page":"467","article-title":"Variceal bleeding is associated with reduced risk of severe cholestasis in primary biliary cirrhosis","volume":"71","author":"Thornton","year":"1989","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib36","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","article-title":"Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival","volume":"96","author":"Gores","year":"1989","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2008.02.008_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2036.2005.02318.x","article-title":"Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years","volume":"21","author":"Chan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.cld.2008.02.008_bib39","first-page":"2314","article-title":"Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis","volume":"91","author":"Batts","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hep.510300315","article-title":"The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis","volume":"30","author":"Combes","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib41","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib43","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00042737-199906000-00005","article-title":"Evidence-based therapy of primary biliary cirrhosis","volume":"11","author":"Heathcote","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(03)00243-5","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression","volume":"39","author":"Paumgartner","year":"2003","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0168-8278(94)80111-8","article-title":"Effects of ursodeoxycholic acid after 4 to 12\u00a0years of therapy in early and late stages of primary biliary cirrhosis","volume":"21","author":"Leuschner","year":"1994","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib49","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib50","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hep.21795","article-title":"Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study","volume":"46","author":"Jackson","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2008.02.008_bib51","first-page":"2063","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am\u00a0J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","article-title":"Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis","volume":"99","author":"Combes","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib53","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/hep.21871","article-title":"Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom","volume":"46","author":"Corpechot","year":"2007","journal-title":"Hepatology"},{"issue":"9184","key":"10.1016\/j.cld.2008.02.008_bib54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cld.2008.02.008_bib55","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002234.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gluud","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib57","first-page":"392","article-title":"Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis","volume":"89","author":"Simko","year":"1994","journal-title":"Am J Gastroenterol"},{"issue":"9204","key":"10.1016\/j.cld.2008.02.008_bib58","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cld.2008.02.008_bib59","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/jhep.2001.20894","article-title":"Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center","volume":"33","author":"Liermann Garcia","year":"2001","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cld.2008.02.008_bib61","first-page":"A628","article-title":"Transplantation among primary biliary cirrhosis patients from 1995 to 2004","volume":"44","author":"Lee","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hep.510290116","article-title":"Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis","volume":"29","author":"Pasha","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.46.1.121","article-title":"Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment","volume":"46","author":"Leuschner","year":"2000","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.cld.2008.02.008_bib64","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/j.1572-0241.2001.05270.x","article-title":"Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?","volume":"96","author":"Angulo","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2008.02.008_bib65","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/j.1572-0241.2006.00695.x","article-title":"Identification of a novel 974C\u2192G nonsense mutation of the MRP2\/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids","volume":"101","author":"Corpechot","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00544371","article-title":"Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis","volume":"28","author":"Hoensch","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib68","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"8638","key":"10.1016\/j.cld.2008.02.008_bib69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF01300759","article-title":"Treatment of pruritus of primary biliary cirrhosis with rifampin","volume":"36","author":"Podesta","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib71","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long-term rifampicin administration in primary biliary cirrhosis","volume":"102","author":"Bachs","year":"1992","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"issue":"4 Suppl","key":"10.1016\/j.cld.2008.02.008_bib73","first-page":"A490","article-title":"Sulindac and its sulfone derivative inhibit colon cancer via modification of intestinal bile acids","volume":"110","author":"Batta","year":"1996","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2008.02.008_bib74","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00042737-200212000-00014","article-title":"The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study","volume":"14","author":"Leuschner","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4 Part 2","key":"10.1016\/j.cld.2008.02.008_bib75","first-page":"337A","article-title":"Correcting biliary phenotype in cystic fibrosis mice: norursodeoxycholic acid but not UDCA normalizes hepatic bile pH and increases bile flow in G1551D CF mice","volume":"36","author":"Broderick","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0168-8278(92)90065-W","article-title":"A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results","volume":"15","author":"Mitchison","year":"1992","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib78","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","article-title":"Oral budesonide for treatment of autoimmune chronic active hepatitis","volume":"8","author":"Danielsson","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib79","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib80","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib81","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib82","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib83","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2007-979472","article-title":"Guidelines for therapy of autoimmune liver disease","volume":"27","author":"Ishibashi","year":"2007","journal-title":"Semin Liver Dis"},{"issue":"5 Pt 1","key":"10.1016\/j.cld.2008.02.008_bib84","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0016-5085(76)80250-8","article-title":"A prospective controlled trial of azathioprine in primary biliary cirrhosis","volume":"70","author":"Heathcote","year":"1976","journal-title":"Gastroenterology"},{"issue":"5 Pt 1","key":"10.1016\/j.cld.2008.02.008_bib85","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0016-5085(80)90784-2","article-title":"Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial","volume":"78","author":"Crowe","year":"1980","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib86","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2008.02.008_bib87","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0016-5085(86)90183-6","article-title":"Randomized trial of chlorambucil for primary biliary cirrhosis","volume":"91","author":"Hoofnagle","year":"1986","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2008.02.008_bib88","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1478-3231.2005.01026.x","article-title":"Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study","volume":"25","author":"Levy","year":"2005","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib90","first-page":"84","article-title":"Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis","volume":"44","author":"Wolfhagen","year":"1994","journal-title":"Neth J Med"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2008.02.008_bib92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Review article: drug development in inflammatory bowel disease: budesonide\u2014a model of targeted therapy","volume":"11","author":"Hamedani","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.cld.2008.02.008_bib94","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib95","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/0016-5085(88)90373-3","article-title":"Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis","volume":"95","author":"Minuk","year":"1988","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.cld.2008.02.008_bib96","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib97","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(93)90422-9","article-title":"Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial","volume":"104","author":"Lombard","year":"1993","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/gast.1999.0029900395","article-title":"Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol","volume":"117","author":"Bonis","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib99","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(05)80004-2","article-title":"Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone","volume":"18","author":"Buscher","year":"1993","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib100","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2006.03048.x","article-title":"Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy","volume":"24","author":"Babatin","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"4 Pt 1","key":"10.1016\/j.cld.2008.02.008_bib101","first-page":"1158","article-title":"The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study","volume":"22","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","article-title":"The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone","volume":"27","author":"Gonzalez-Koch","year":"1997","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1572-0241.2003.07173.x","article-title":"Methotrexate therapy for primary biliary cirrhosis","volume":"98","author":"Bach","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib104","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/gast.1999.0029900400","article-title":"Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial","volume":"117","author":"Hendrickse","year":"1999","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2008.02.008_bib105","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2008.02.008_bib106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0016-5085(94)90085-X","article-title":"Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis","volume":"107","author":"Sharma","year":"1994","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib107","first-page":"295","article-title":"Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis","volume":"91","author":"Bergasa","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/s-2005-916326","article-title":"Future Treatment Options in PBC","volume":"25","author":"Vierling","year":"2005","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.cld.2008.02.008_bib109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","article-title":"Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine","volume":"33","author":"Richardson","year":"2000","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2008.02.008_bib110","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00042737-199910000-00015","article-title":"Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis","volume":"11","author":"Jones","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2008.02.008_bib111","first-page":"168","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2008.02.008_bib112","first-page":"550A","article-title":"Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA)","volume":"46","author":"Meyers","year":"2007","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932610800024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932610800024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T01:49:26Z","timestamp":1708912166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932610800024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S108932610800024X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2008.02.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}